Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125772272 | 12577227 | 2 | F | 20150329 | 20160907 | 20160720 | 20160914 | EXP | FR-PFIZER INC-2015180808 | PFIZER | 43.00 | YR | M | Y | 99.00000 | KG | 20160914 | OT | FR | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125772272 | 12577227 | 1 | SS | PF-00547659 | INVESTIGATIONAL PRODUCT | 1 | Subcutaneous | 75 MG, EVERY 4 WEEKS | 0 | 75 | MG | SOLUTION FOR INJECTION | |||||||
| 125772272 | 12577227 | 2 | SS | PF-00547659 | INVESTIGATIONAL PRODUCT | 1 | Subcutaneous | 225 MG, EVERY 4 WEEKS | 0 | 225 | MG | SOLUTION FOR INJECTION | |||||||
| 125772272 | 12577227 | 3 | PS | METHOTREXATE SODIUM. | METHOTREXATE SODIUM | 1 | UNK | 11719 | |||||||||||
| 125772272 | 12577227 | 4 | SS | Imurel | AZATHIOPRINE SODIUM | 1 | UNK | 0 | |||||||||||
| 125772272 | 12577227 | 5 | SS | CIMZIA | CERTOLIZUMAB PEGOL | 1 | UNK | 0 | |||||||||||
| 125772272 | 12577227 | 6 | SS | REMICADE | INFLIXIMAB | 1 | UNK | 0 | |||||||||||
| 125772272 | 12577227 | 7 | SS | HUMIRA | ADALIMUMAB | 1 | UNK | 0 | |||||||||||
| 125772272 | 12577227 | 8 | SS | GSK1605786A | VERCIRNON SODIUM | 1 | UNK (PLACEBO OR GSK1605786A) | 0 | |||||||||||
| 125772272 | 12577227 | 9 | SS | GSK1605786A | VERCIRNON SODIUM | 1 | UNK (GSK1605786A) | 0 | |||||||||||
| 125772272 | 12577227 | 10 | SS | USTEKINUMAB | USTEKINUMAB | 1 | UNK | 0 | |||||||||||
| 125772272 | 12577227 | 11 | C | OROCAL D3 | CALCIUM CARBONATECHOLECALCIFEROL | 1 | Oral | 400 MG, DAILY | 0 | 400 | MG | ||||||||
| 125772272 | 12577227 | 12 | C | HYDROCORTISONE. | HYDROCORTISONE | 1 | Oral | 30 MG, DAILY | 0 | 30 | MG | ||||||||
| 125772272 | 12577227 | 13 | C | HYDROCORTISONE. | HYDROCORTISONE | 1 | 0 | ||||||||||||
| 125772272 | 12577227 | 14 | C | TACROLIMUS. | TACROLIMUS | 1 | Oral | 7 MG, 2X/DAY | 1316 | MG | 0 | 7 | MG | BID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125772272 | 12577227 | 1 | Crohn's disease |
| 125772272 | 12577227 | 11 | Osteoporosis prophylaxis |
| 125772272 | 12577227 | 12 | Adrenal insufficiency |
| 125772272 | 12577227 | 13 | Prophylaxis |
| 125772272 | 12577227 | 14 | Crohn's disease |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125772272 | 12577227 | HO |
| 125772272 | 12577227 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125772272 | 12577227 | Colon cancer | |
| 125772272 | 12577227 | Condition aggravated | |
| 125772272 | 12577227 | Crohn's disease |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125772272 | 12577227 | 1 | 20140122 | 20140219 | 0 | |
| 125772272 | 12577227 | 2 | 20140314 | 20140707 | 0 | |
| 125772272 | 12577227 | 3 | 201305 | 201308 | 0 | |
| 125772272 | 12577227 | 4 | 200511 | 200904 | 0 | |
| 125772272 | 12577227 | 5 | 200605 | 200705 | 0 | |
| 125772272 | 12577227 | 6 | 200706 | 201003 | 0 | |
| 125772272 | 12577227 | 7 | 201005 | 201107 | 0 | |
| 125772272 | 12577227 | 8 | 20111027 | 20120119 | 0 | |
| 125772272 | 12577227 | 9 | 20120120 | 20120706 | 0 | |
| 125772272 | 12577227 | 10 | 201209 | 201304 | 0 | |
| 125772272 | 12577227 | 11 | 20131127 | 0 | ||
| 125772272 | 12577227 | 12 | 20141115 | 0 | ||
| 125772272 | 12577227 | 14 | 20141127 | 201503 | 0 |